ClinicalTrials.gg
CompletedNCT01868997Updated Dec 17, 2024Results posted

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

A Phase 2 interventional study of teprotumumab and normal saline in Thyroid Associated Ophthalmopathies and Thyroid-Associated Ophthalmopathy, sponsored by Amgen. Completed at 15 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.

Enrollment
3rd of 12
88 · median 56
Started
2013
the only one that year
Phase 2
2 of 12
1 open now
Registered
1st of 12
by date
Lead sponsor
10 of 12
Amgen

Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2, and was the 1st registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teprotumumab

teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing teprotumumab in Graves Ophthalmopathy, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.

"Funding Source - FDA OOPD"

Read the detailed description

Study with completed results acquired from Horizon in 2024.

03

Conditions studied

  • Thyroid Associated Ophthalmopathies
  • Thyroid-Associated Ophthalmopathy

Keywords

  • Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated
  • Ophthalmopathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Graves' disease associated with active TED and a clinical activity score of ≥ 4
  • Fewer than 9 months from onset of TED
  • No previous medical or surgical treatment, excluding local supportive measures and oral if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent with at least 6 weeks between last administration of oral steroids and randomization
  • Euthyroid or with mild hypo or hyperthyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below the normal limits (every effort should be made to correct the mild hypo- or hyperthyroidism promptly)

Exclusion criteria

Exclusion Criteria:

  • Optic neuropathy
  • Corneal decompensation unresponsive to medical management
  • Oral or IV treatment for any non-TED reason in the preceding 3 months
  • Poorly controlled diabetes
  • \< 100 x 10\^9/L
  • concentration > 2 g/dL below the lower limit of normal
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.

    Drug: normal saline

  • Experimental
    Teprotumumab

    Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.

    Drug: teprotumumab

Interventions

  • Also known as: RV 001, HZN-001

  • Drugnormal saline
06

What researchers measure

Primary outcomes

  1. Responder Status at Week 24

    Number of participants classified as responders and non-responders at Week 24. Responders were defined as participants with a reduction in clinical activity score (CAS, see Outcome Measure 4 description for details) of ≥ 2 points, and a reduction in proptosis (amount of protrusion of the eye from the orbital rim) of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye. Participants who had no assessment at 24 weeks were considered non-responders.

    Time frame: Week 24

Secondary outcomes

  1. Overall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM])

    The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of thyroid eye disorder (TED) by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. The transformed overall score is the sum of scores from all 16 questions to a scale of 0 (worst health) to 100 (best health).

    Time frame: Baseline to Week 24

  2. Overall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM)

    Proptosis is the amount of protrusion of the eye from the orbital rim. Measurements were recorded using the Hertel exophthalmometer. Participants with a decrease ≥ 2 mm were considered improving, those with an increase or decrease \< 2 mm were considered remaining stable, and those with an increase ≥ 2 mm were considered worsening.

    Time frame: Baseline to Week 24

  3. Overall Average Change From Baseline in CAS to Week 24 (MMRM)

    The 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.

    Time frame: Baseline to Week 24

  4. Overall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM)

    The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Visual Functioning score is the sum of scores from following 8 questions to a scale of 0 (worst health) to 100 (best health): bicycling, driving, moving around the house, walking outdoors, reading, watching television (TV), hobby or pastime, feel hindered.

    Time frame: Baseline to Week 24

  5. Overall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM)

    The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Appearance score is the sum of scores from the following 8 questions to a scale of 0 (worst health) to 100 (best health): feel appearance has changed, feel being stared at, feel people react unpleasantly, influence on self-confidence, feel socially isolated, influence on making friends, appear less often on photos, try to mask changes in appearance.

    Time frame: Baseline to Week 24

07

Results

Posted Aug 30, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboTeprotumumab
Started4542
Completed3836
Not completed76
Withdrew: Adverse event25
Withdrew: Lack of efficacy20
Withdrew: Other31

Outcome measures

PrimaryResponder Status at Week 24

Number of participants classified as responders and non-responders at Week 24. Responders were defined as participants with a reduction in clinical activity score (CAS, see Outcome Measure 4 description for details) of ≥ 2 points, and a reduction in proptosis (amount of protrusion of the eye from the orbital rim) of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye. Participants who had no assessment at 24 weeks were considered non-responders.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Responder Status at Week 24
ParticipantsPlaceboTeprotumumab
Responder929
Non-Responder / Missing3613
Statistical analysis
  • Placebo vs Teprotumumab · Regression, Logistic · p = < 0.001 (Odds ratio, 95% confidence interval, and P-value are obtained from a logistic regression model with treatment and smoking status as covariates.) · Odds ratio (or): 8.86 · 95% CI 3.293 to 23.825
SecondaryOverall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM])

The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of thyroid eye disorder (TED) by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. The transformed overall score is the sum of scores from all 16 questions to a scale of 0 (worst health) to 100 (best health).

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Overall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM])
units on a scalePlaceboTeprotumumab
Overall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM])6.77 ± 2.25117.74 ± 2.423
Statistical analysis
  • Placebo vs Teprotumumab · Mixed-Model Repeated Measures · p = 0.001 · Difference in least squares mean: 10.97 · 95% CI 4.561 to 17.375
SecondaryOverall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM)

Proptosis is the amount of protrusion of the eye from the orbital rim. Measurements were recorded using the Hertel exophthalmometer. Participants with a decrease ≥ 2 mm were considered improving, those with an increase or decrease \< 2 mm were considered remaining stable, and those with an increase ≥ 2 mm were considered worsening.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mm
Overall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM)
mmPlaceboTeprotumumab
Overall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM)-0.15 ± 0.188-2.46 ± 0.200
Statistical analysis
  • Placebo vs Teprotumumab · Mixed-Model Repeated Measures · p = < 0.001 · Difference in least squares mean: -2.31 · 95% CI -2.843 to -1.772
SecondaryOverall Average Change From Baseline in CAS to Week 24 (MMRM)

The 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Overall Average Change From Baseline in CAS to Week 24 (MMRM)
units on a scalePlaceboTeprotumumab
Overall Average Change From Baseline in CAS to Week 24 (MMRM)-1.85 ± 0.172-3.43 ± 0.181
Statistical analysis
  • Placebo vs Teprotumumab · Mixed-Model Repeated Measures · p = < 0.001 · Difference in least squares mean: -1.59 · 95% CI -2.073 to -1.098
SecondaryOverall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM)

The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Visual Functioning score is the sum of scores from following 8 questions to a scale of 0 (worst health) to 100 (best health): bicycling, driving, moving around the house, walking outdoors, reading, watching television (TV), hobby or pastime, feel hindered.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Overall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM)
units on a scalePlaceboTeprotumumab
Overall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM)7.51 ± 2.64621.67 ± 2.891
Statistical analysis
  • Placebo vs Teprotumumab · Mixed-Model Repeated Measures · p = < 0.001 · Difference in least squares mean: 14.16 · 95% CI 6.549 to 21.773
SecondaryOverall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM)

The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Appearance score is the sum of scores from the following 8 questions to a scale of 0 (worst health) to 100 (best health): feel appearance has changed, feel being stared at, feel people react unpleasantly, influence on self-confidence, feel socially isolated, influence on making friends, appear less often on photos, try to mask changes in appearance.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Overall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM)
units on a scalePlaceboTeprotumumab
Overall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM)6.60 ± 2.65612.92 ± 2.836
Statistical analysis
  • Placebo vs Teprotumumab · Mixed-Model Repeated Measures · p = 0.101 · Difference in least squares mean: 6.32 · 95% CI -1.255 to 13.901

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population: Placebo0/44 (0%)1/44 (2.3%)21/44 (47.7%)
Safety Population: Teprotumumab0/43 (0%)5/43 (11.6%)25/43 (58.1%)
Most frequent serious events
Most frequent serious events
EventSafety Population: PlaceboSafety Population: Teprotumumab
DiarrheaGastrointestinal disorders0/441/43
Inflammatory bowel diseaseGastrointestinal disorders0/441/43
Escherichia sepsisInfections and infestations0/441/43
Hashimoto's encephalopathyNervous system disorders0/441/43
Urinary retentionRenal and urinary disorders0/441/43
Optic neuropathyEye disorders1/440/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSafety Population: PlaceboSafety Population: Teprotumumab
NauseaGastrointestinal disorders4/448/43
Muscle spasmsMusculoskeletal and connective tissue disorders2/448/43
FatigueGeneral disorders6/443/43
DiarrhoeaGastrointestinal disorders2/445/43
HyperglycaemiaMetabolism and nutrition disorders2/445/43
Upper respiratory tract infectionInfections and infestations4/440/43
DizzinessNervous system disorders4/440/43
RashSkin and subcutaneous tissue disorders4/443/43
Weight decreasedInvestigations0/443/43
DysgeusiaNervous system disorders0/443/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTeprotumumabTotal
Mean54.1 ± 12.8751.7 ± 10.7852.9 ± 11.90
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTeprotumumabTotal
Female362864
Male91423
08

Study locations

15 sites
  • Jules Stein Eye Institute at UCLA
    Los Angeles, California 90095, United States
  • University of Denver
    Aurora, Colorado 80045, United States
  • Emory University Department of Ophthalmology
    Atlanta, Georgia 30322, United States
  • University of Iowa Hospitals and Clinics, Department of Ophthalmology
    Iowa City, Iowa 52242, United States
  • Kellogg Eye Center at University of Michigan
    Ann Arbor, Michigan 48105, United States
  • Washington University Department of Ophthalmology
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center Department of Ophthalmology
    Omaha, Nebraska 68198, United States
  • Casey Eye Institute at Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Hamilton Eye Institute at University of Tennessee
    Memphis, Tennessee 38163, United States
  • Eye Wellness Center
    Houston, Texas 77005, United States
  • Medical College of Wisconsin, The Eye Institute
    Milwaukee, Wisconsin 53226, United States
  • Johannes Gutenberg University Medical Center
    Mainz, 55101, Germany
  • Fondazione Ca' Granda Ospedale Policlinico Graves GO Center
    Milan, 20122, Italy
  • University of Pisa, Azienda Ospedaliera
    Pisa, 56100, Italy
  • Moorfields Eye Hospital
    London, United Kingdom
09

References and documents

Publications

  • Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. PubMed 28467880 ↗
  • Xin Y, Xu F, Gao Y, Bhatt N, Chamberlain J, Sile S, Hammel S, Holt RJ, Ramanathan S. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. Clin Pharmacokinet. 2021 Aug;60(8):1029-1040. doi: 10.1007/s40262-021-01003-3. Epub 2021 Mar 26. PubMed 33768488 ↗
  • Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014 Mar 20;55(3):1735-48. doi: 10.1167/iovs.14-14002. PubMed 24651704 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in Mar 2016, 32 months.

Results were first posted in Aug 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2013
First posted
Jun 5, 2013
StartActual
Jul 2013
Primary completionActual
Mar 2016
CompletionActual
Feb 22, 2017
Results first posted
Aug 30, 2017
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01868997
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 5, 2013
Start date
Jul 2013
Primary completion
Mar 2016
Completion
Feb 22, 2017
Results posted
Aug 30, 2017
Last update
Dec 17, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion